| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Truist Securities analyst David Macdonald reiterates Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from...
																	RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:THC) with a Outperform and raises the price target from $23...
																	
																	UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $238 to $260.
																	Cantor Fitzgerald analyst Sarah James maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target fr...
																	Guggenheim analyst Jason Cassorla maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $221 to ...
																	Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech...
																	
																	Tenet Healthcare (NYSE:THC) raises FY2025 GAAP EPS guidance from $14.05-$15.15 to $14.66-$15.37 vs $14.78 analyst estimate..